The Fund supports networks of state health policy decision makers to help identify, inspire, and inform policy leaders.
The Milbank Memorial Fund supports two state leadership programs for legislative and executive branch state government officials committed to improving population health.
The Fund identifies and shares policy ideas and analysis to advance state health leadership, strong primary care, and sustainable health care costs.
Keep up with news and updates from the Milbank Memorial Fund. And read the latest blogs from our thought leaders, including Fund President Christopher F. Koller.
The Fund publishes The Milbank Quarterly, as well as reports, issues briefs, and case studies on topics important to health policy leaders.
The Milbank Memorial Fund is is a foundation that works to improve population health and health equity.
September 2024 (Volume 102)
Quarterly Article
Caroline Horrow
Aaron S. Kesselheim
Sep 18, 2024
June 2024
Back to The Milbank Quarterly
Policy Points:
The dangers of faulty laboratory tests have been highlighted recently because of reporting on the collapse of Theranos owing to fraudulent claims about its blood tests1 and a New York Times investigation finding 85% false-positive rate among prenatal tests.2 Patients have learned in these and other cases, including around the COVID-19 pandemic, that many of the tests they trust for their clinical care have never been formally evaluated by the Food and Drug Administration (FDA).3 Perhaps the most common of these non–FDA-reviewed tests are laboratory-developed tests (LDTs), which are “designed, manufactured and used within a single laboratory.”4
After years of calls for reform, the Verifying Accurate Leading-edge IVCT [In Vitro Clinical Test] Development (VALID) Act of 2022,5, 6 which was championed by the FDA and some congressional leaders, seemed to portend a change in the FDA’s approach to LDTs. The VALID Act would have overhauled regulation of LDTs, but it failed to get through Congress, including in a year-end Food and Drug Omnibus Reform Act signed by President Biden in December 2022. After another push in 2023,7 the legislation stalled again. In 2024, the FDA finalized regulation on its own, intending to pursue some overhaul by regulation what could not be achieved through legislative reform.8 In this article, we discuss the rationale for changes to oversight of LDTs and the potential impact of some of the key proposals pursued by Congress and the FDA, first in the VALID Act and then in recently finalized regulatory changes.